Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TA99-TNFα
- Development stage
- Preclinical
- Lead developer
- ETH Zurich
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TA99-TNFα is an immunocytokine consisting of the TA99 monoclonal antibody fused to tumor necrosis factor-alpha (TNFα). The TA99 antibody component specifically targets gp75 (also known as tyrosinase-related protein 1 or TYRP1), a glycoprotein highly expressed on the surface of melanoma cells. By delivering TNFα directly to the tumor microenvironment, the fusion protein aims to induce pro-inflammatory changes, increase the recruitment and activation of immune effector cells such as natural killer (NK) cells, and enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Developed by researchers at ETH Zürich, TA99-TNFα has demonstrated the ability to inhibit tumor growth and potentiate the activity of intact IgG antibodies in preclinical melanoma models.
- Other names
- TA99-TNFaTA-99-TNFaTA 99-TNFaTA99-TNF-alphaTA-99-TNF-alphaTA 99-TNF-alpha
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TYRP1 (Tyrosinase-related protein 1)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on TA99-TNFα.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TA99-TNFα.